Effect of Aldosterone-Producing Adenoma on Endothelial Function and Rho-Associated Kinase Activity in Patients With Primary Aldosteronism

The purpose of this study was to evaluate vascular function and activity of Rho-associated kinases (ROCKs) in patients with primary aldosteronism. Vascular function, including flow-mediated vasodilation (FMD) and nitroglycerine-induced vasodilation, and ROCK activity in peripheral leukocytes were evaluated in 21 patients with aldosterone-producing adenoma (APA), 23 patients with idiopathic hyperaldosteronism (IHA), and 40 age-, sex-, and blood pressure–matched patients with essential hypertension (EHT). FMD was significantly lower in the APA group than in the IHA and EHT groups (3.2±2.0% versus 4.6±2.3% and 4.4±2.2%; P<0.05, respectively), whereas there was no significant difference in FMD between the IHA and EHT groups. There was no significant difference in nitroglycerine-induced vasodilation in the 3 groups. ROCK activity was higher in the APA group than in the IHA and EHT groups (1.29±0.57 versus 1.00±0.46 and 0.81±0.36l; P<0.05, respectively), whereas there was no significant difference in ROCK activity between the IHA and EHT groups. FMD correlated with age (r=−0.31; P<0.01), plasma aldosterone concentration (r=−0.35; P<0.01), and aldosterone:renin ratio (r=−0.34; P<0.01). ROCK activity correlated with age (r=−0.24; P=0.04), plasma aldosterone concentration (r=0.33; P<0.01), and aldosterone:renin ratio (r=0.46; P<0.01). After adrenalectomy, FMD and ROCK activity were restored in patients with APA. APA was associated with both endothelial dysfunction and increased ROCK activity compared with those in IHA and EHT. APA may have a higher risk of future cardiovascular events.

[1]  P. Vanhoutte,et al.  State of the Art Lecture , 2018, European Psychiatry.

[2]  A. Nakashima,et al.  Rho-Associated Kinase Activity Is a Predictor of Cardiovascular Outcomes , 2014, Hypertension.

[3]  P. Plouin,et al.  Cardiovascular Complications Associated With Primary Aldosteronism: A Controlled Cross-Sectional Study , 2013, Hypertension.

[4]  A. Nakashima,et al.  Nitroglycerine-Induced Vasodilation for Assessment of Vascular Function: A Comparison With Flow-Mediated Vasodilation , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[5]  K. Chayama,et al.  Mineralocorticoid Receptor Blocker Eplerenone Improves Endothelial Function and Inhibits Rho‐Associated Kinase Activity in Patients With Hypertension , 2012, Clinical pharmacology and therapeutics.

[6]  Yukihito Higashi,et al.  Rho-Associated Kinase Activity, Endothelial Function, and Cardiovascular Risk Factors , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[7]  Katsutoshi Takahashi,et al.  Guidelines for the diagnosis and treatment of primary aldosteronism--the Japan Endocrine Society 2009. , 2011, Endocrine journal.

[8]  T. Masuyama,et al.  Aldosterone induces interleukin-18 through endothelin-1, angiotensin II, Rho/Rho-kinase, and PPARs in cardiomyocytes. , 2008, American journal of physiology. Heart and circulatory physiology.

[9]  A. Nishiyama,et al.  Possible Involvement of Rho-Kinase in Aldosterone-Induced Vascular Smooth Muscle Cell Remodeling , 2008, Hypertension Research.

[10]  A. Nishiyama,et al.  Involvements of Rho-kinase and TGF-beta pathways in aldosterone-induced renal injury. , 2006, Journal of the American Society of Nephrology : JASN.

[11]  T. Tagami,et al.  Molecular Mechanism of the Inhibitory Effect of Aldosterone on Endothelial NO Synthase Activity , 2006, Hypertension.

[12]  Kunihiro Suzuki,et al.  Aldosterone Impairs Vascular Endothelial Cell Function , 2006, Journal of cardiovascular pharmacology.

[13]  M. Young,et al.  Mechanisms of Mineralocorticoid Action , 2005, Hypertension.

[14]  B. Kingwell,et al.  Low-Renin Hypertension With Relative Aldosterone Excess Is Associated With Impaired NO-Mediated Vasodilation , 2005, Hypertension.

[15]  N. de Las Heras,et al.  Eplerenone reduces oxidative stress and enhances eNOS in SHR: vascular functional and structural consequences. , 2005, Antioxidants & redox signaling.

[16]  P. Milliez,et al.  Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. , 2005, Journal of the American College of Cardiology.

[17]  Maristela L Onozato,et al.  Eplerenone Shows Renoprotective Effect by Reducing LOX-1–Mediated Adhesion Molecule, PKC&egr;-MAPK-p90RSK, and Rho-Kinase Pathway , 2005, Hypertension.

[18]  A. Zeiher,et al.  Endothelial Function: Cardiac Events , 2005, Circulation.

[19]  J. Liao,et al.  Inhibition of Rho-Kinase Leads to Rapid Activation of Phosphatidylinositol 3-Kinase/Protein Kinase Akt and Cardiovascular Protection , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[20]  A. Struthers,et al.  Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment , 2004, Heart.

[21]  R. Loberg,et al.  Rho/Rho Kinase and Phosphoinositide 3-Kinase Are Parallel Pathways in the Development of Spontaneous Arterial Tone in Deoxycorticosterone Acetate-Salt Hypertension , 2004, Journal of Pharmacology and Experimental Therapeutics.

[22]  Y. Kanno,et al.  Effects of Eplerenone on Heart and Kidney in Two-Kidney, One-Clip Rats , 2004, American Journal of Nephrology.

[23]  K. Chayama,et al.  Endothelial function and oxidative stress in renovascular hypertension. , 2002, The New England journal of medicine.

[24]  K. Chayama,et al.  Excess Norepinephrine Impairs Both Endothelium-Dependent and -Independent Vasodilation in Patients With Pheochromocytoma , 2002, Hypertension.

[25]  A. Takeshita,et al.  Possible Involvement of Rho-Kinase in the Pathogenesis of Hypertension in Humans , 2001, Hypertension.

[26]  M. Morissette,et al.  Increased Expression and Activity of RhoA Are Associated With Increased DNA Synthesis and Reduced p27Kip1 Expression in the Vasculature of Hypertensive Rats , 2001, Circulation research.

[27]  G. Kajiyama,et al.  A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study. , 2000, Journal of the American College of Cardiology.

[28]  G. Kajiyama,et al.  Regular aerobic exercise augments endothelium-dependent vascular relaxation in normotensive as well as hypertensive subjects: role of endothelium-derived nitric oxide. , 1999, Circulation.

[29]  K. Williams,et al.  Atherosclerosis--an inflammatory disease. , 1999, The New England journal of medicine.

[30]  A. Hall,et al.  Rho GTPases and the actin cytoskeleton. , 1998, Science.

[31]  Shuh Narumiya,et al.  Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension , 1997, Nature.

[32]  K. Kaibuchi,et al.  Formation of Actin Stress Fibers and Focal Adhesions Enhanced by Rho-Kinase , 1997, Science.

[33]  E. Schiffrin,et al.  Comparison of effects of angiotensin I-converting enzyme inhibition and beta-blockade for 2 years on function of small arteries from hypertensive patients. , 1995, Hypertension.

[34]  L. Ghiadoni,et al.  Aging and endothelial function in normotensive subjects and patients with essential hypertension. , 1995, Circulation.

[35]  M. Creager,et al.  Effect of captopril and enalapril on endothelial function in hypertensive patients. , 1994, Hypertension.

[36]  A. Quyyumi,et al.  Role of Endothelium‐Derived Nitric Oxide in the Abnormal Endothelium‐Dependent Vascular Relaxation of Patients With Essential Hypertension , 1993, Circulation.

[37]  T. Lüscher,et al.  Activation of endothelial L-arginine pathway in resistance arteries. Effect of age and hypertension. , 1990, Hypertension.

[38]  A. Quyyumi,et al.  Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. , 1990, The New England journal of medicine.

[39]  T. Lüscher,et al.  Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension. , 1990, Circulation.

[40]  T. Lüscher Imbalance of endothelium-derived relaxing and contracting factors. A new concept in hypertension? , 1990, American journal of hypertension.

[41]  R. Furchgott Role of endothelium in responses of vascular smooth muscle. , 1983, Circulation research.

[42]  N. Zhang The Diagnosis and Treatment of Primary Aldosteronism , 2011 .

[43]  西坂 麻里 Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism , 2008 .

[44]  T. Ogihara,et al.  Converting enzyme inhibitor improves forearm reactive hyperemia in essential hypertension. , 1997, Hypertension.